LY3849891

· Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LY3849891, covering 2026-01-22 to 2026-01-22. Get the full timeline:

Most recent: Clinical Trial Update: A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) [Phase 1]

See pricing